TOP > 外国特許検索 > MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR

MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR NEW

外国特許コード F200010102
整理番号 4567
掲載日 2020年5月18日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP059461
国際公開番号 WO 2015147204
国際出願日 平成27年3月26日(2015.3.26)
国際公開日 平成27年10月1日(2015.10.1)
優先権データ
  • 特願2014-066716 (2014.3.27) JP
発明の名称 (英語) MEDICINAL COMPOSITION INHIBITING NEOVASCULARIZATION PROLIFERATION FACTOR NEW
発明の概要(英語) Provided are a medicinal composition for neovascular diseases, a medicinal composition inhibiting neovascularization proliferation factor, and utilization of these compositions. In one or more embodiments, the present invention provides a medicinal composition that comprises, as an active ingredient, a low molecular compound capable of suppressing the expression of a VEGF gene in cells or reducing the production of a VEGF protein by cells. In one or more embodiments, the present invention provides a medicinal composition that comprises, as an active ingredient, a compound represented by general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of the same.
従来技術、競合技術の概要(英語) BACKGROUND ART
As a disease associated with angiogenesis, retinal choroidal neovascularization disease or cancer has been known. Choroidal neovascularization disease of the retina of one 1 is a representative disease is age-related macular degeneration. Age-related macular degeneration is, at the center of the retina with age-related macular disease will cause the modification portion. The first cause of blindness in Japan and at position 3 and also, the number of patients in Japan is estimated 69 million people. With the elderly, in increasing the number of the patient. Age-related macular degeneration is exudative, pathological choroidal neovascularization (CNV) is thought to be the cause. In addition, causes the death of the cancer is Japan which occupies about 3 interrupt, the prevalence is increasing by the elderly. Many cancer and solid tumors, solid tumors at the new namachi tumor generated in the tube, into tumor cells in oxygen and nutrient supply, the tumor is increased. In tumor cells intrude and new namachi tube, through the large blood vessels, tumor cell migration to distant to the organ, so-called Metastasis. In other words the tumor angiogenesis is the cause of a deterioration occurs in the gun is.
Non-patent document 1 is, disclosed in Patent Document 1 with respect to the phosphorylation SRPK-inhibiting effect and an enzyme, and, the compound having anti-viral effect, can be inhibited angiogenesis in the retina is disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • 発明者(英語)
  • HAGIWARA Masatoshi
  • MOROOKA Satoshi
  • HOSOYA Takamitsu
  • YOSHIDA Suguru
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close